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The recent work focuses on the physical characterization 
and dissolution study of PGV-0 loaded self-nanoemulsifying drug 
delivery system (SNEDDS). The PGV-0 SNEDDS was prepared by 
spontaneous emulsification method using oleic acid, tween 
20:labrasol (1:1) and polyethylene  glycol  400. The zeta 
potential of the PGV-0 SNEDDS was -34.4±7.66 mv. The 
nanoemulsion of PGV-0 SNEDDS was thermodynamically stable 
with forming droplet oil containing PGV-0 in it and spherical. The 
dissolution result showed that the dissolution profile of SNEDDS 
PGV-0 was dissimilar with the PGV-0 powder in AGF and AIF. The 
PGV-0 SNEDDS was able to increase the dissolution significantly 
(p <0.05) compared with PGV-0 powder of 44.13% in AGF 
medium and 30.37% in AIF medium. It is concluded that 
SNEDDS formulation was able to improve the dissolution profile 
of PGV-0. 
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INTRODUCTION 
Administration of an antiinflammatory 
agent is very commonly used for a variety of 
inflammatory conditions and diseases. One of 
the potent antiinflammatory drug candidates is 
pentagamavunon-0. Unlike the NSAIDs that 
are known to have an irritating effect on the 
stomach, PGV-0 is safe for the stomach 
(Wahyuni, 1999).  
PGV-0 is highly soluble in DMSO, easily 
soluble in 0.01-0.1N NaOH, poorly soluble in 
ethyl acetate, methanol and ethanol, and 
practically insoluble in water with a solubility of 
7.04 x 10-7 M, n-hexane, carbon tetrachloride, 
benzene, toluene and diethyl ether (Soediman, 
2003; Yuwono and Oetari, 2005). The 
molecular weight of PGV-0 is 352.13 (Nugroho 
et al., 2009). PGV-0 is unstable in aqueous 
solution, its shelf life is only 45.3 hours, a half-
life of 299 hours and its activation energy is 
14.2 kcal mol-1 (Yuwono and Oetari, 2005). 
The molecular weight of PGV-0 is 352.13 
(Nugroho et al., 2009). PGV-0 is unstable in 
aqueous solution, its shelf life is only 45.3 
hours, half-life of 299h. PGV-0 has a log value 
of permeability (log P) 1.84 (Yuwono and 
Oetari, 2005). According to Wahyuningsih, the 
apparent permeability constant (Papp) value of 
PGV-0 obtained from the in situ absorption 
test is 1.91x 10-4cm/sec (Wahyuningsih, 2003), 
which means that PGV-0 has a high 
permeability (>10-5 cm/sec). Although it has a 
high permeability value, so it is easily absorbed 
orally, but its bioavailability is low. This is due 
to its low solubility in water and its high 
metabolism (Hakim et al., 2006). PGV-0 
undergoes glucuronidation and sulfation in 
vitro, whereas in vivo, the above two reactions 
only occur in the PGV-0 metabolite which still 
has a hydroxyl group (Sugiyanto et al., 2005).  
Poor dissolution is a prime determinant 
of the rate and extent of drug absorption. 
Hence, to improve the dissolution of PGV-0, a 
novel formulation technology called self nano-
emulsifying drug delivery system (SNEDDS) 
was applied to PGV-0. In this regard, PGV-0 is 
dissolved in a nano-sized droplet of oil in the 
gastrointestinal tract so that the interface area 
in contact with gastrointestinal fluid and 
membranes is increased. Oil droplets 
containing PGV-0 as lipophilic drugs can be 
transported through the lymphatic system 
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which bypasses the liver to avoid first pass 
metabolism (Kohli, et al., 2010). Along with the 
ability of the surfactant to modify the 
absorption of the gastrointestinal membrane in 
a reversible manner so that the membrane 
becomes more permeable (Bruesewit, et al., 
2007), these three result in an increase in the 
amount of absorbed and available drugs in the 
blood. 
Bringing forward with the part one of the 
present studies, that particularly deals with the 
formulation development and optimization, part 
two demonstrates the physical characteristics 
and dissolution performance of the developed 
formulation. The characteristics of SNEDDS 
was assessed for the morphological and droplet 
size, the zeta potential and the physical stability 
of the nanoemulsion.  
 
MATERIALS AND METHODS 
The material used in this study was 
PGV-0 from Curcumin Research Center UGM. 
The excipients purchased from Bratachem were 
the oils (oleic acid, VCO, soybean oil, olive oil), 
surfactants (tween 20, span 80, and tween 80) 
and cosurfactants (PEG 400). Labrafil and 
labrafac as oils, labrasol (surfactant), and 
transcutol (cosurfactant) were kindly provided 
by Gattefosse (France) via PT Mensa Group 
(Jakarta). Myritol (oil) and kolliphor (surfactant) 
were purchased from PT BASF Indonesia 
(Jakarta). All excipients were pharmaceutical 
grade. Liquid chromatography grade of 
methanol and hydrochloric acid was purchased 
from Merck. Magnesium chloride, calcium 
chloride, potassium chloride, sodium chloride, 
sodium hydrogen chloride, all the reagents were 
pro analysis grade,  were obtained from 
Laboratorium Penelitian dan Pengujian 
Terpadu (LPPT) UGM.  
 
Excipients selection for SNEDDS 
formulation  
The excipients selection for the PGV-0 
SNEDDS formulation was reported by Astuti 
(2017). Briefly, the excipients were selected 
based on the ability to dissolve PGV-0 and  
self-nanoemulsifying properties. The PGV-0 
solubility test was carried out by UV-Vis 
spectrophotometric method using methanol as 
the solvent. The oil, surfactant, and cosurfactant 
having the highest ability to dissolve PGV-0 
were mixed and introduced to the water for the 
self-emulsification assessment. The disper-
sability, the time to complete emulsification and 
any phase separation were evaluated visually. 
The % transmittance of the emulsion was 
measured by visible-spectrophotometric method 
(Astuti, et al., 2017). 
 
Preparation of PGV-0 SNEDDS 
Referring to the previous work (Astuti, 
2017), the optimized PGV-0 SNEDDS 
formulation was prepared by using oleic acid, 
tween 20:labrasol (1:1) and PEG 400 as oil, 
surfactant, and cosurfactant, respectively. In a 
glass vial, a mixture of oleic acid (1.86 mL), 
tween 20:labrasol (1:1) (5.14 mL), and PEG  
400 (3mL) was vortexed for 1min until 
homogenous. An accurately weighed of PGV-0 
(163.5 mg) was added to the mixture, vortexed 
for 1min followed by sonication until the PGV-
0 powder was dissolved.  
 
Morphology imaging of nanodroplet by 
TEM 
The morphology of PGV-0 SNEDDS 
droplet was observed by transmission electron 
microscope (TEM). Briefly, PGV-0 SNEDDS 
was diluted and carefully mixed with distilled 
water in the ratio of 1:25 to obtained an 
emulsion sample. The emulsion was passed 
through the 0.22 membrane filter and allowed 
to stand for 2h to achieve the equilibrium. The 
sample then negatively stained with 1% 
aqueous phosphotungstic acid.  One drop of 
the sample was placed in a copper grid and 
visualized under the TEM.  
 
Zeta potential measurement 
Nanoemulsion sample of PGV-0 
SNEDDS was prepared by adding 100µL of 
PGV-0 SNEDDS to 100mL of distilled water, 
mixed by magnetic stirrer until the emul-
sification point was reached. PSA instrument 
was prepared for zeta potential measurement. 
The zeta potential was measured at a 
wavelength of 633nm, temperature of 25°C, 
and a refractive index of dispersant was 1.33. 
 
Physical stability determination 
One hundred PGV-0 SNEDDS was 
added to 100 mL distilled water, artificial 
intestinal fluid (AIF), and artificial gastric fluid 
(AGF) respectively. The mixture then 
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homogenized with vortex for 30s. The resultant 
mixtures were observed every hour for 4h to 
determine their stability. The physical stability 
was characterized by the absence of aggregates, 
precipitates, and phase separation. 
The AIF was containing 0.1523 MgCl2, 
0.1470g CaCl2, 0.0931g KCl, 1.75850g NaCl, 
0.4200g NaHCO3 in 500mL distilled water CO2 
free. While the AGF was containing 1.00g 
NaCl and 1.3g HCl in 500mL distilled water 
CO2 free. 
 
Comparative dissolution profile  
The dissolution profile of PGV-0 SNEDDS 
was compared with PGV-0 powder.  PGV-0 
SNEDDS sample was prepared by loading an 
accurately measured of 0.581mL PGV-0 
SNEDDS equivalent to 9.5mg PGV-0 into a 
capsule size "0". As a comparison was 9.5mg of 
PGV-0 powder, loaded into capsule size “5”. 
The dissolution assay was performed using 
apparatus type II (paddle) dissolution apparatus 
with 500mL of different dissolution media 
(AGF and AIF). The medium temperature was 
set to 37±0.5°C and the rotation speed was 50 
rpm. At minute 0, the capsule was introduced 
into the medium, then at 5, 10, 15, 20, 30, 45 
and 60min, 5mL of solution was taken and 
replaced again with an equivalent volume of the 
same dissolution medium type at the same 
temperature. The experiment was performed in 
a triple.  
 
Data Analysis 
The physical characteristics were 
evaluated based on the applicable requirements. 
The extent of PGV-0 released in the 45th-min 
value (C45) were analyzed using IBM SPSS 
statistic 23 software. The normality of data 
distribution was determined by Kolmogorof-
Smirnof test, followed by a one-way anova with 
95% confidence level and Least Significant 
Difference (LSD). P<0.05 was considered as 
the statistically significant difference. The 
dissolution profiles were compared using a 
similarity factor (f2) calculated by equation 1 
(FDA, 2017). 
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Where Rt and Tt are the percentage of PGV-0 
dissolved at each sampling time point for               
the PGV-0 SNEDDS and PGV-0                
powder, respectively; n=number of sampling 
time point. 
 
RESULT AND DISCUSSION 
Excipient selection and PGV-0 SNEDDS 
preparation 
Referring to the previous reports (Astuti, 
2017), the best oil, surfactant, and cosurfactant 
for PGV-0 SNEDDS formulation was oleic 
acid, tween 20:labrasol (1:1), and PEG 400, 
respectively. The selected excipient showed the 
highest ability to dissolve PGV-0. When they 
were mixed as a SNEDDS blank then 
introduced to the water, in less than 2min the 
emulsion was formed completely. The emulsion 
showed a transparent appearance with the 
highest % transmittance, i.e 92.88%, 92.75% 
and 93.90% in water, AGF and AIF, 
respectively. The optimum formulation 
obtained based on the desirability value showed 
the optimum ability to dissolve PGV-0, droplet 
size and C45 (Astuti, 2017). 
 
TEM image of PGV-0 SNEDDS 
A TEM photograph of PGV-0 
SNEDDS nanoemulsion (Figure 1) which 
shows the spherical droplets with the droplet 
size are about 50nm. This size is smaller than 
the droplet size measured by dynamic light 
scattering (DLS), ie 189.7nm (average size). A 
possible reason for this difference could be 
aggregating of the droplets in the dilute 
emulsion (1:1000) when observed under DLS. 
According to Kumar and Kumbhat, the 
comparison of size data obtained from DLS to 
TEM images can be used to determine the 
aggregation state. In an unaggregated emulsion, 
the DLS-measured diameter is similar or 
slightly larger than the TEM size, and much 
larger and often accompanied by high 
polydispersity index when particle aggregation 
occurs (Kumar and Kumbhat, 2016). The 
polydispersity index of PGV-0 SNEDDS 
measured  by    DLS   was found  to be 0.462±0.08, 
still below 0.5, so, the PGV-0 SNEDDS can be 
considered to have good stability. The inside of 
droplets are darker denotes PGV-0 dissolved in 
it. The spheric shape shows the low of the 
interface force droplet-water, that is beneficial 
for absorption process because of droplet 
Ika Yuni Astuti 
Volume 29 Issue 2 (2018)   63 
contact with enterocyte membrane surface 





Figure 1. The morphology of PGV-0 SNEDDS 




The potential zeta value can be used to 
estimate the surface characteristics of the 
nanoemulsion. In the range of more than 
30mV or less than -30mV, nanoemulsion 
shows stability, because the attractive and 
repulsive forces prevent particles approaching 
each other closely. The obtained zeta potential 
of the PGV-0 SNEDDS was -31.5 to -34.4mv, 
so, the PGV-0 SNEDDS is considered 




Figure 2. Physical stability of PGV-0 SNEDDS 
nanoemulsion at 25° C in medium (a) distilled 
water, (b) AGF, and (c) AIF. 
 
Stability of the PGV-0 SNEDDS in 
distilled water, AGF, and AIF 
The addition of PGV-0 SNEDDS into 
various media produces nanoemulsion which 
remains translucent without aggregation or 
precipitation up to 4h as (Figure 2. This 
indicates good physical stability of PGV-0 
SNEDDS. 
 
Dissolution profile of PGV-0 SNEDDS 
and PGV-0 powder comparison 
The comparison of the dissolution 
profile of PGV-0 SNEDDS with PGV-0 
powder (Figure 3). The PGV-0 SNEDDS is 
able to release PGV-0 in the faster time and in 
a greater extent than PGV-0 powder. Within 
the first 5min, 40% of PGV-0 has been 
released from SNEDDS, continuing to the 
120min, more than 80% of PGV-0 has been 
released. In contrast, the PGV-0 powder is 
slow in releasing PGV-0, so until at the end of 
the study ie at 240min, the PGV-0 released 
from the powder is less than 4%. In the 
240min, the ratio of PGV-0 released from 
SNEDDS PGV-0 and PGV-0 powder is 44.13 




Figure 3. The comparison of dissolution 
profiles of PGV-0 SNEDDS with PGV-0 
powder in AGF medium and AIF medium. 
 
The C45 of PGV-0 SNEDDS in AGF is 
78%. This extent of dissolution is meet the 
requirement set by WHO, i.e for the immediate 
release preparation,  at least 75% of the active 
substance is dissolved in 45min (Kuwana, 
2007).  
ANOVA statistic analysis followed by 
LSD test on C45 parameter using SPSS program 
at 95% confidence level indicated that the C45 
of PGV-0 SNEDDS in both AGF (78%) and 
AIF (73%) were significantly higher than PGV-
0 powder in AGF (2.22%) and AIF (1.65%) 
(Table I). These results are in line with the 
similarity factor results. In the AGF medium, 
the dissolution profile of PGV-0 SNEDDS 
shows a lack of similarity with the PGV-0 
powder (f2 <50), as well as in the AIF medium.  
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This shows that the SNEDDS formulation could 
improve the dissolution profile of PGV-0.  
The C45 of the PGV-0 powder in AGF 
did not differ significantly within AIF, in line 
with the similarity factor of both curves (f2 > 
50). The similarity factor of dissolution profile 
of PGV-0 SNEDDS in AGF and in AIF also 
showed a similarity (f2>50). Although the C45 
of both later curves is significantly different, 
overall it can be concluded that the dissolution 
profile of  PGV-0 SNEDDS and PGV-0 
powder was not affected by the medium 
difference (AGF and AIF). The C45 only 
measures the single point dissolution test, while 
the similarity factor in this study measured the 
13 points dissolution test, so the dissolution 
profile comparison can characterize the 
formulation more precisely. 
The dissolution of PGV-0 SNEDDS is 
much higher than that of PGV-0 powder 
because in aqueous media PGV-0 SNEDDS 
forms nanoemulsions that keep PGV-0 
remained homogeneously dispersed for some 
time in the bulk medium in the form of 
nanodroplets. While the PGV-0 powder is 
almost insoluble in the medium and is mostly 
located at the bottom of the container as a 
precipitate. The enhancement in the dissolution 
of the SNEDDS dosage form was reported by 
many studies, among others by Cui (2009) who 
reported that within 20 minutes, 96% of the 
curcumin was detached from the SNEDDS 
preparation compared with the release of less 
than 2% of curcumin powder during 60 
minutes of observation. 
 
CONCLUSION 
Formed PGV-0 SNEDDS was 
thermodynamically stable with forming droplet 
oil containing PGV-0 in it and spherical. The 
SNEDDS formulation was able to improve the 
PGV-0 dissolution profile. 
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